<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">HOFFMANN, MICHAEL</style></author><author><style face="normal" font="default" size="100%">REITZ, DANIEL</style></author><author><style face="normal" font="default" size="100%">TAUGNER, JULIAN</style></author><author><style face="normal" font="default" size="100%">ROENGVORAPHOJ, OLARN</style></author><author><style face="normal" font="default" size="100%">KÄSMANN, LUKAS</style></author><author><style face="normal" font="default" size="100%">EZE, CHUKWUKA</style></author><author><style face="normal" font="default" size="100%">KARIN, MONIKA</style></author><author><style face="normal" font="default" size="100%">BELKA, CLAUS</style></author><author><style face="normal" font="default" size="100%">MANAPOV, FARKHAD</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2319-2322</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14198</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: We investigated blood parameters in patients with inoperable stage III non-small cell lung cancer (NSCLC) to predict individual outcomes after definitive chemoradiotherapy (CRT). Patients and Methods: Blood parameters of consecutive patients undergoing definitive CRT between 2010 and 2016 for inoperable stage III NSCLC before multimodal treatment and at first follow-up were measured and analyzed. Results: Blood parameters from 99 patients were evaluated. Histologically, about 50% of patients had an adenocarcinoma. All patients received platinum-based sequential or concurrent CRT. The median total dose to the primary tumor was 60 (range=48-70) Gy. On multivariate analysis after adjustment for all co-founders, median overall survival for pre-treatment cutoffs were: lactate dehydrogenase (LDH) &gt;250 U/l was 17 vs. 27 months [hazard ratio (HR)=2.05, 95% confidence intervaI (CI)=1.15-3.66; p=0.015], thrombocytosis &gt;400×106/l: 11 vs. 23 months (HR=2.75, 95% CI=1.1-6.88; p=0.03), hypoalbuminemia &lt;3.5 g/dl: 12 vs. 24 months (HR=2.42, 95% CI=1.21-4.84; p=0.013) and post-treatment neutrophilia &gt;7×106/l: 12 vs. 27 months (HR=2.5, 95% CI=1.21-5.17; p=0.013). Conclusion: Pre-treatment elevated LDH, thrombocytosis, hypoalbuminemia and post-treatment neutrophilia were associated with significantly worse overall survival in patients with inoperable stage III NSCLC treated with CRT. Patients with both pre-therapeutic elevated LDH and hypoalbuminemia demonstrated a dismal prognosis despite completion of multimodal treatment.</style></abstract></record></records></xml>